VEGFA and head and neck squamous cell carcinoma: Cohen et al showed that the combination of erlotinib and anti‐VEGF (a humanized monoclonal antibody bevacizumab) is well tolerated in recurrent or metastatic HNSCC, where a few patients achieved a favorable response.51